Drugs
Therapeutics and drugs enable prevention, stabilization, and definitive treatment across military medicine: antimicrobials for battlefield infections and AMR mitigation, hemostatic agents and analgesics for hemorrhage and pain control, neuroprotectants for TBI, antitoxins and antivirals for biothreats, and optimized dosing/formulations for austere and prolonged-field care.
Technical Challenges
Rapid infection control in the presence of antimicrobial resistance and biofilm-associated wound infections.
Effective hemorrhage control and analgesia with limited supplies and delayed evacuation.
Stability, storage, and cold-chain dependence for biologics and antitoxins in austere environments.
Limited point-of-care pharmacokinetic/therapeutic drug monitoring to guide dosing in variable physiology (shock, burns, hypothermia).
Emerging Opportunities
Long-acting, temperature-stable formulations for prophylaxis and acute care to reduce resupply burden.
Rapidly deployable antitoxins, antivirals, and broad-spectrum antimicrobials for emergent biothreats.
Field-capable assays and decision support to personalize dosing during prolonged or distributed care.
Drugs and adjuncts specifically tailored to blast polytrauma, TBI, and multiorgan dysfunction encountered in combat.
Current and Emerging Technologies in Drugs
AI-driven discovery and drug repurposing
Machine learning and in silico screening accelerate identification of candidate therapeutics and repurposed drugs for infections, neuroprotection, and hemostasis, shortening transition from bench to field-ready studies.
Long-acting and temperature-stable formulations
Injectable depot formulations, transdermal systems, and stabilizing excipients extend duration and remove cold-chain constraints for prophylactics, antimicrobials, and analgesics.
Novel antimicrobials and anti-biofilm agents
New classes, bacteriophage therapies, antimicrobial peptides, and biofilm-disrupting adjuncts target resistant wound and device-associated infections common in combat casualties.
On-demand biologics and cell-free manufacturing
Portable platforms for rapid synthesis of antitoxins, monoclonal antibodies, and personalized biologics reduce dependence on central production during outbreaks or supply disruption.
Point-of-care pharmacokinetics and therapeutic drug monitoring
Rapid assays and decision-support tools enable individualized dosing in shock, burn, and hypothermia to avoid under- or overdosing in prolonged-field-care scenarios.
Advanced delivery systems
Novel routes (inhaled, intranasal, microneedle patches, targeted nanoparticles) improve rapid administration, absorption, and triage-level care when IV access is limited.
Importance to Military Medicine
Improve survival from combat injury
Hemostatic agents, analgesics, antimicrobials and resuscitative drugs are life-saving interventions during the initial window after trauma.
Enable prolonged and distributed care
Stable, long-acting drugs and field-capable dosing guidance extend effective care when evacuation is delayed or infrastructure is limited.
Counter biological threats and maintain readiness
Rapid therapeutics for emerging pathogens, antitoxins, and mitigations for AMR protect force health and mission continuity.
Optimize physiological performance and recovery
Neuroprotective agents, rekindled wound-healing therapeutics, and pharmacologic performance aids support return-to-duty and long-term functional outcomes.
Alignment with the MTEC Mission
MTEC accelerates transition of drug candidates and delivery technologies that address DoD priorities—combat casualty care, infectious-disease resilience, prolonged-field-care solutions, and readiness—by connecting military needs, academic science, industry scale-up, and rapid evaluation pathways.
Dual-Use (Military + Civilian) Applications
Dual-use therapeutics benefit both Warfighters and civilians: battlefield antimicrobials inform hospital AMR strategies; long-acting prophylactics support public-health mass prophylaxis.
Portable biologic production and rapid antitoxin platforms have clear civilian utility during outbreaks and in remote health systems.
Point-of-care drug monitoring and dosing decision-support reduce medication errors in both austere military settings and resource-limited civilian hospitals.
Advanced delivery technologies (microneedles, aerosols) expand access to emergency therapeutics for civilians and deployed forces alike.
Explore MTEC Members with Drugs Capabilities
MTEC members — spanning biotech, pharma, academic translational labs, and military clinical research centers — bring complementary strengths: rapid R&D, GMP manufacturing scale-up, regulatory strategy, and field evaluation pathways. Explore member profiles to identify partners for therapeutic discovery, formulation engineering, on-site biologic production, and clinical validation.
102 Members with Drugs capabilities.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
Nuclera develops automated benchtop platforms and integrated systems for rapid protein expression, optimization, and purification, utilizing cell-free synthesis, digital microfluidics, and software-driven workflows. Their technology enables miniaturized and scalable protein prototyping—including challenging targets such as membrane proteins—directly at the lab bench. Nuclera serves academic and industrial researchers, focusing on reducing turnaround time for functional protein access and streamlining screening and production. The company has secured significant funding to enable broad commercialization, expanded their leadership team to support scale-up, and continues to drive advancements in drug discovery, proteomics, and experimental automation.
FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.
STAT Therapeutics is focused on developing a drug- device combination for easy, rapid administration of intramuscular, life-saving medications by users in any setting, aiming to improve access and usability for acute emergency treatments such as pain, anaphylaxis, and seizures.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections. With a focus on addressing the global antibiotic resistance crisis, Armata leverages its proprietary bacteriophage-based technology to develop high-impact, best-in-class phage therapeutics. The company operates from a 56,000 square foot facility in Los Angeles, California, equipped for phage product development from bench to clinic. Armata's team of microbiologists and scientists work on discovering natural phages and enhancing them through synthetic biology and engineering to create tailored drug products for clinical trials.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
Seek Labs is a biotechnology company headquartered in Salt Lake City, Utah, dedicated to advancing scientific discovery and delivering universal healthcare solutions. The company specializes in next-generation point-of-care molecular diagnostics and programmable CRISPR-based therapeutics, aiming to bridge the gap between disease outbreak and intervention. Powered by its proprietary AI discovery engine, BioSeeker™, Seek Labs is building a modular, full-stack system that enables rapid response to emerging pathogens, scalable precision treatments, and accessible diagnostics. The company is committed to global health innovation, sustainability, and community engagement, and is a proud member of Utah's BioHive life sciences ecosystem. Seek Labs' mission is to empower individuals with healthcare solutions tailored to their specific needs, revolutionizing the detection and treatment of diseases for both human and animal health.
The Institute for Integrative & Innovative Research (I3R) at the University of Arkansas is dedicated to pioneering solutions to complex societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I3R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
Action Medical Technologies is a pharmaceutical and medical device company focused on developing innovative solutions that integrate medications with advanced devices and injector systems to improve patient outcomes, particularly in austere prehospital environments.
Vindhya Data Science is a women-owned small business headquartered in North Carolina, USA, with a presence in RTP and Boston. We specialize in bioinformatics, genomics, artificial intelligence, and data engineering, cheminformatics, evidence-based medicine, epidemiology and related disciplines. Vindhya partners with federal government agencies, leading academic medical centers, and pharma/biotech organizations to transform large datasets into informed decisions using advanced data science technologies. With over 100 years of combined experience, 150+ publications, and 73+ successful projects, Vindhya is committed to delivering impactful solutions in the life sciences sector.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Memsel is a biotechnology research and development company dedicated to enhancing health and combatting infections through advanced phage therapies and targeted delivery systems. The company aims to transform healthcare solutions across human, animal, and plant domains, addressing critical health challenges and antibiotic resistance.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.
Astrocyte Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders. The company focuses on harnessing the potential of astrocytes, the brain's natural caretaker cells, to treat brain injuries and diseases. Their flagship program, AST-004, aims to significantly reduce early brain damage and is currently in Phase 2 clinical trials.
Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.
Evimero is an interdisciplinary company focused on understanding the interactions between microorganisms and human health, agriculture, and the environment, utilizing Systems Biology and AI/ML. Evimero applies molecular principles to infectious disease and microbiome science to improve health outcomes and environmental sustainability through targeted interventions in dysbiotic microbiomes and in people with infectious disorders. Evimero has an infectious disease product pipeline including both prophylactic and diagnostic assets against common causes of Travelers' Diarrhea, including a unique approach to preventing infection with human Norovirus, enterotoxigenic E. coli (ETEC) and others. Evimero's pipeline of drugs targeting human and animal microbiomes includes early-stage assets aimed at generalized microbiome-driven inflammation and gut leak, and specific disease-targeted disorders including Parkinson Disease and Inflammatory Bowel Diseases. Evimero's platform also makes possible a suite of point-of-care diagnostics that can be used for patient cohorting (infectious diseases), risk stratification, and ultimately informing therapeutic decision-making. The nature of Evimero's platform assures a steady stream of novel assets targeting both infectious diseases and chronic disorders with roots in microbiome dysfunction.
Kane Biotech is a Canadian-based biotechnology company focused on the research, development, and commercialization of products that prevent and remove microbial biofilms. Established in 2001, the company aims to improve human and animal welfare through innovative solutions to biofilm-related challenges and antimicrobial resistance. With a strong portfolio of 54 patents and patents pending, Kane Biotech is recognized as a leader in biofilm research and technology, and is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTC Markets under the symbol 'KNBIF'.
Innospera Pharma is a privately held biotechnology company based in Montreal, focused on developing small-molecule modulators targeting G-protein coupled receptors (GPCRs), particularly GPR84 and GPR40, for the treatment of chronic, fibrotic, inflammatory, and metabolic diseases. Its pipeline includes next-generation lipid-mimetic compounds designed to address unmet medical needs, with lead candidates intended for conditions such as idiopathic pulmonary fibrosis and various cardiometabolic disorders. The company leverages extensive scientific expertise and preclinical data and is supported by investors such as Investissement Québec, Seido Capital, and Anges Québec.
Vivosang Inc is an investigational stage biotechnology company focused on developing pegylated human hemoglobin products to enhance oxygen delivery in medical applications, particularly in traumatic hemorrhagic injuries. Their lead product, VS-101, aims to provide targeted oxygen delivery to tissues in need, addressing significant medical needs in emergency and surgical settings.
Exponent is a multidisciplinary science and engineering consulting firm serving sectors including healthcare, energy, manufacturing, and consumer products. From medical devices, pharmaceuticals, and supplements to digital health and wearables, we deliver rigorous science that quantifies impacts on human health. Exponent helps you push the envelope on the development, deployment, safety, and effectiveness of cutting-edge drugs, devices, and diagnostics — concomitantly balancing benefits and risks. Count on our multidisciplinary, data-driven, evidence-based assessments to give you clarity on your most complex product needs and challenges. With lives on the line, innovations that support healthcare demand the highest levels of scientific rigor. Whether you’re developing a novel drug, a sturdier stent, or a faster flu test, you need clear answers to complex questions, quickly. Exponent supports our life sciences clients across the total product lifecycle by solving critical design, regulatory, safety, and market access challenges. We can collaborate with you throughout your journey, helping you navigate risks and opportunities — and optimize outcomes — with science-based strategies and specialized expertise.
Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
Purgo Scientific is a medical device company dedicated to developing effective solutions for the biofilm infections crisis in orthopedic surgery. Their mission is to provide a locally targeted sustained delivery device that ensures the right therapy is delivered to the right place for the right duration, ultimately improving patient outcomes and reducing the impact of surgical site infections.
The University of North Carolina Wilmington (UNCW) is a top doctoral and research institution located in Wilmington, North Carolina. Established in 1947, UNCW has grown to serve nearly 18,000 students and employs about 2,500 staff. The university is dedicated to providing a powerful academic experience that fosters creative inquiry, critical thinking, and thoughtful expression in a beautiful coastal setting. UNCW is committed to educational excellence, community engagement, and global connections, making it a vibrant part of the southeastern North Carolina community. UNCW also emphasizes the importance of freedom of expression and mutual respect within its diverse community.
The University of Missouri-Kansas City (UMKC) is dedicated to transforming today's learners into tomorrow's leaders through innovative education, research, and community engagement. With over 125 academic programs, UMKC fosters a diverse and inclusive environment that empowers students to achieve their goals and make a positive impact in their communities.
Mayo Clinic is the largest integrated, not-for-profit medical group practice in the world, dedicated to providing high-quality, patient-centered care. With a history of innovation spanning nearly 150 years, Mayo Clinic is committed to transforming healthcare through research, education, and compassionate care, ensuring that the best possible treatment is available to everyone.
Draper is an independent nonprofit engineering innovation company with a legacy spanning over 90 years, dedicated to delivering transformative solutions for national security, prosperity, and global challenges. Renowned for its pioneering work in guidance, navigation, and control (GN&C) systems, Draper partners with government, industry, and academia to engineer advanced technologies in space, defense, biotechnology, and electronic systems. The company leverages multidisciplinary expertise, digital engineering, and a collaborative approach to provide field-ready prototypes, mission-critical systems, and innovative research. Draper’s mission is to ensure the nation's security and prosperity by delivering sustainable, cutting-edge solutions that address the toughest problems of today and tomorrow, while fostering an inclusive and diverse workforce. Draper also invests in the next generation of innovators through robust educational programs, including internships, co-ops, and the Draper Scholars Program, integrating academic research with real-world problem-solving.
Since its founding in 1878, Shionogi has been dedicated to developing innovative treatments to improve the lives of patients worldwide. The company focuses on addressing global health challenges, including antimicrobial resistance and COVID-19, through a commitment to scientific excellence and strategic partnerships.
Temple University is Philadelphia’s only public university and a global center of academic excellence. It is classified as an R1 institution, indicating very high research activity, and offers over 600 academic programs across 17 diverse schools and colleges. The university is committed to providing accessible education that fosters positive change and prepares students to become leaders in their fields. Additionally, Temple emphasizes a vibrant campus life enriched by arts, culture, and a commitment to diversity and inclusivity. The university also promotes a tobacco-free environment to enhance the health and well-being of its community. Temple's athletics program further enhances student life, with 19 varsity teams competing at the NCAA Division I level, fostering school spirit and community engagement.
The Office of Sponsored Projects Administration (OSPA) at the University of Kentucky is dedicated to transforming tomorrow by streamlining grants and contracts. OSPA provides essential services to faculty and staff, including assistance with proposal preparation, award negotiation, and compliance with sponsor policies.
Southwest Research Institute (SwRI) is a nonprofit research and development organization that provides independent, premier services to government and industry clients. Founded in 1947, SwRI is committed to advancing science and technology to benefit humanity, focusing on innovative solutions that improve human health and safety. With a diverse range of technical divisions, SwRI addresses complex challenges in various fields including mechanical engineering, materials, aerospace, automotive, biomedical, and more.
Celestial Therapeutics is a Johnson & Johnson Innovations-JLABS resident California-based biotechnology company focused on developing innovative therapies to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The company leverages groundbreaking science to create dual-modal antivirals/anti-inflammatories, mRNA vaccines, and therapeutics. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies, aiming to address significant unmet medical needs worldwide.
Persist AI is a biotechnology company pioneering the use of AI-driven robotics to accelerate and transform pharmaceutical formulation development. Their mission is to deliver life-saving drugs faster, with fewer side effects, and improved patient outcomes by leveraging advanced automation, machine learning, and high-throughput experimentation. Persist AI's integrated platform addresses the bottlenecks of traditional drug formulation by combining custom robotics, computational chemistry, and proprietary AI models, enabling rapid, scalable, and cost-effective development of complex drug delivery systems such as long-acting injectables. With a global presence and a team of experts in drug delivery, automation, and machine learning, Persist AI is committed to making advanced drug delivery systems more accessible and efficient for the pharmaceutical industry worldwide. The company also demonstrates a strong commitment to data protection, privacy, and security, implementing robust technical and organizational measures in compliance with international standards.
Molecular You is a pioneer in predictive, preventative, and precision health, providing advanced molecular analysis to empower individuals and healthcare providers with actionable health insights. Founded in 2014 as a spin-off from the Personalized Medicine Initiative in Vancouver, BC, the company leverages cutting-edge proteomics, metabolomics, and AI to analyze over 250 blood-based biomarkers. Their mission is to make molecular medicine simple, accessible, and impactful, enabling early detection of disease risks and supporting personalized, data-driven health decisions. Molecular You serves both clinics and individuals, offering comprehensive health assessments, personalized action plans, and ongoing progress tracking to foster proactive, transparent, and preventative care. The company’s platform is rooted in rigorous scientific validation, peer-reviewed research, and advanced multi-omic analysis, setting a new standard for precision health and population health management. Molecular You’s unique systems biology approach analyzes interconnected pathways—such as metabolic, cardiovascular, immune, neurological, and hormonal health—providing a holistic view of health that goes far beyond traditional lab tests. Their direct-to-consumer platform enables at-home blood draws and digital health dashboards, and their Action Plan translates biomarker data into tailored, science-backed recommendations for diet, supplements, and lifestyle. The platform’s comprehensive biomarker coverage and AI-driven insights empower both patients and providers to detect and address health concerns long before symptoms arise.
Macro Biologics, Inc. is dedicated to designing, patenting, and producing macro biologics, which are large molecule biologics with both physical properties and functional activities. These biologics are composed of natural building blocks, such as amino acids or carbohydrates, and are designed to degrade back into their natural components, making them environmentally friendly. The company aims to address significant global challenges, such as antibiotic resistance and pollution, by providing biologics that are safe for both people and the environment. Macro Biologics is committed to the highest standards of science, medicine, and business, with a focus on healthcare applications.
The University of Arizona Applied Research Corporation (UA-ARC) is a non-profit organization affiliated with the University of Arizona, dedicated to leveraging the university's strengths in research and education to address national security challenges. UA-ARC aims to deliver innovative solutions and foster collaborations between academia, industry, and government.
Lumen Bioscience is dedicated to unlocking the full potential of biologic drugs by transforming their development, cost, and accessibility. Utilizing patented technology, Lumen aims to develop biologic drugs faster, safer, and more effectively than traditional methods, addressing diseases that have been neglected by conventional drug-making tools.
Frontier Bio creates lab-grown human tissues to reduce the worldwide organ shortage. Their first clinical product is a tissue-engineered vascular graft made from the patient's own cells.
The University of Utah (UU) is a leading research institution recognized for its research activity and commitment to innovation and discovery. As an R1 Institution, it is dedicated to advancing knowledge and solving critical problems that challenge our national security interests and impact the global community. We foster interdisciplinary collaboration and provide resources to drive transformative research focused on enhancing medical care superiority for the U.S. Department of Defense (DoD) through advanced medical and engineering research sponsored by our Applied Medical & Engineering Laboratory (AM&E Lab). As a leading public university, UU also provides healthcare services to seven states in the Intermountain West, with the largest catchment of remote and austere frontier territory for any academic center. Leveraging its geographic advantage, technological and commercialization strengths, expertise in medical services, and leading-edge, core engineering competencies, UU is uniquely positioned to address the nation's critical national security interests.
Lixa is a biotech company dedicated to resolving recurring microbial infections and contaminations by addressing the global challenge of antimicrobial resistance (AMR). The company is pioneering a technology platform called NeoX™, which aims to restore the effectiveness of existing antimicrobials and biocides against resistant bacteria. Lixa's mission is to develop scalable, cost-effective solutions that can be applied across various sectors, including human, animal, plant, marine, and industrial applications, to combat AMR and improve global health.
The Institute for Biohealth Innovation (IBI) at George Mason University unites over 300 faculty and thousands of students across 34 departments to advance human health and well-being through innovative research. The IBI focuses on major health challenges, including infectious diseases, cancer, brain and behavior, and cardiovascular health, collaborating with national and international partners to implement solutions that enhance health outcomes.
Microbiotix, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery and development of proprietary small molecule drugs targeting serious infectious diseases, including multi-drug resistant pathogens. The company is recognized for its innovation and has consistently been a top recipient of NIH awards among Massachusetts biotech/pharma companies.
The University of Minnesota's Research and Innovation Office (RIO) serves as a central resource for conducting, managing, and sponsoring research. It aims to facilitate collaborative research that addresses complex problems and promotes innovations that improve lives. RIO oversees research compliance and administration, fostering a culture of integrity and ethical practices in research. Additionally, RIO is committed to enhancing research capacity through various funding opportunities and strategic initiatives, including the management of specialized facilities for biocontainment research.
The University of Notre Dame, founded in 1842, is a prestigious Catholic research university located in South Bend, Indiana. It is dedicated to providing a holistic education that integrates faith, reason, and service to others. The university aims to be a leading global Catholic research institution, fostering a community of scholars committed to inquiry, justice, and the common good.
New York University (NYU) is a global university that connects talented and ambitious individuals in some of the world's greatest cities. Its mission is to be a top-quality institution, providing a diverse range of academic programs and opportunities for students to engage with the world's challenges. NYU is committed to fostering innovation and entrepreneurship, and it emphasizes diversity, equity, and inclusion in its educational mission. Founded in 1831, NYU has evolved to become a leader in higher education, with a commitment to accessibility and a diverse student body. NYU offers a wide array of academic programs, including accelerated studies and online education, catering to the needs of a global student population.
The Wyss Institute for Biologically Inspired Engineering uses biological design principles to develop new engineering innovations that will transform medicine and create a more sustainable world. At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.
Vasomune Therapeutics is a private clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases associated with vascular dysfunction. Their lead drug candidate, Pegevongitide (AV-001), enhances the body's ability to reverse vascular endothelial instability and vascular leak, particularly in conditions such as Acute Respiratory Distress Syndrome (ARDS), hemorrhage, and following toxin exposure.
Northwestern University is a prestigious institution dedicated to fostering a diverse and inclusive environment, promoting academic excellence, and engaging in impactful research. With campuses in Evanston, Chicago, and Doha, Qatar, Northwestern emphasizes global engagement and community involvement, preparing students to tackle complex challenges through interdisciplinary collaboration and innovative thinking.
The University of Iowa is dedicated to providing a comprehensive educational experience that fosters academic excellence, research opportunities, and a vibrant student life. With a commitment to accessibility and inclusivity, the university aims to prepare its students for success in various fields while promoting a supportive community.
Case Western Reserve University is dedicated to solving the biggest issues of today and tomorrow through innovative research and education. With a commitment to experiential learning, the university offers a wide range of programs and opportunities for students to engage in research, internships, and community service, all within a vibrant campus located in Cleveland, Ohio.
The University of Alaska Fairbanks (UAF) is a Land, Sea, and Space Grant university and an international center for research, education, and the arts, emphasizing the circumpolar North and its diverse peoples. UAF integrates teaching, research, and public service as it educates students for active citizenship and prepares them for lifelong learning and careers.
New Jersey Institute of Technology (NJIT) is a leading public research university dedicated to providing students with a world-class education in STEM fields and beyond. With a commitment to academic excellence, NJIT prepares students to be leaders in the most in-demand fields through innovative programs, expert faculty, and extensive research opportunities. NJIT is recognized for its affordability and return on investment, making it a top choice for students seeking a quality education. NJIT is also ranked among the top public universities in the nation, known for its diverse student body and commitment to fostering an inclusive environment.
ClearCure Biosciences is a clinical-stage biopharmaceutical company focused on developing non-toxic, first-in-class and best-in-class therapies for cancer, infectious diseases, sepsis, neurological diseases, and cardiovascular conditions. The company emphasizes drugging challenging targets, leveraging proprietary small molecules, nanotechnology, new oncology cell therapies, new transdermal drug delivery technology, AI and omics-driven approaches, and digital health solutions to address serious unmet medical needs. The company is currently seeking collaborators and partnerships.
The University of Arkansas for Medical Sciences Office of Research and Sponsored Programs (ORSP) is dedicated to supporting UAMS faculty in acquiring, performing, and administering projects funded by external sources. The ORSP ensures compliance with policies, negotiates award terms, liaises between investigators and sponsors, and manages subcontracts.
Founded by Thomas Jefferson in 1819, the University of Virginia is a prestigious public university that emphasizes the advancement of human knowledge, education of leaders, and cultivation of an informed citizenry. It is recognized for its commitment to academic excellence, vibrant student life, and a strong alumni network, making it one of the top public universities in the United States.
The University of Missouri is dedicated to advancing research, innovation, and impact through a comprehensive support system for faculty, students, and staff. It aims to foster collaboration, enhance economic development, and promote entrepreneurship, while ensuring compliance with research regulations and ethical standards. The university also emphasizes the importance of interdisciplinary partnerships and provides resources to support veteran entrepreneurs through programs like the Entrepreneurship Bootcamp for Veterans.
Viscus Biologics LLC specializes in product realization from ideation to high volume production, manufacturing components, devices, and products with natural polymer and extracellular matrix materials. The company aims to fulfill patient and market needs, improve quality of life, and restore tissue to a healthy state.
Kimer Med is a New Zealand-based biotechnology company dedicated to ending the suffering caused by viral diseases through the development of safe and effective broad-spectrum antiviral therapeutics. Leveraging their proprietary platform for rapid antiviral drug design, Kimer Med targets the significant unmet need for treatments against the vast majority of human-infecting viruses, where 95% currently lack approved therapies. Among 21 viruses in total, they have demonstrated efficacy against all four serotypes of Dengue, as well as Zika virus, and a lead candidate is being advanced toward clinical trials. Kimer Med’s mission is to revolutionize antiviral treatment and enhance global health security by providing new, host-directed medical countermeasures to address currently untreatable viral diseases, and to stockpile for pandemic preparedness.
The University of Massachusetts Lowell (UML) is dedicated to providing a comprehensive educational experience that prepares students for success in their careers and lives. With over 200 degree programs and a commitment to research and community engagement, UML fosters a vibrant learning environment for its diverse student body.
Aphios is a green biotechnology company focused on developing enabling nanotechnology platforms and enhanced therapeutics for health maintenance, disease prevention, and treatment of various conditions including cancers, infectious diseases, and central nervous system (CNS) disorders. The company emphasizes environmentally-sustainable practices and aims to improve the quality of life through innovative therapies.
The University of Nebraska Medical Center (UNMC) is dedicated to transforming lives through premier educational programs, innovative research, and extraordinary patient care. Founded in 1869, UNMC is a leader in health sciences education and research, serving as a vital resource for Nebraska and beyond.
Southern Research (SR) is a nonprofit preclinical contract research institute that has been bridging basic science and commercial solutions for over 80 years. From pioneering chemotherapy research in collaboration with Memorial Sloan Kettering to generating millions of data points in the global fight against COVID-19, SR has consistently been at the forefront of scientific innovation. Our team of experts excels in transforming cutting-edge science into tangible societal benefits, utilizing comprehensive drug discovery and development capabilities to drive innovation and advance life-saving medical breakthroughs. SR collaborates with over 100 industrial partners, the federal government, and numerous academic institutions to advance the development of life-saving medicines.
MassBiologics, part of UMass Chan Medical School, is the only nonprofit, FDA-licensed manufacturer of vaccines and biologics in the United States. With over 100 years of experience, it is dedicated to improving public health through the research, development, and production of biologic products, including vaccines and monoclonal antibodies.
Ceres Nanosciences, Inc. is a privately held company based in Northern Virginia, specializing in the development and commercialization of Nanotrap® hydrogel particle technology. Their mission is to deliver innovative products powered by Nanotrap Technology to address life science needs and provide better patient outcomes. Ceres' products enable the capture, concentration, and preservation of low-abundance analytes from diverse biological and environmental samples, supporting applications in diagnostics, research, and public health surveillance. The company is ISO 9001:2015 certified and collaborates with leading research institutions, public health agencies, and industry partners to advance global health security and biosecurity. Ceres has established a national network of Wastewater-based Epidemiology Centers of Excellence and has received significant funding from the NIH RADx initiative and other organizations to expand its impact in underserved communities. Their technology is widely adopted for wastewater-based epidemiology, proteomics, and nucleic acid analysis, with a strong focus on supporting public health monitoring, early detection of infectious diseases, and environmental bio-surveillance.
The Medical University of South Carolina (MUSC) is South Carolina’s premier biomedical research institution, dedicated to advancing health through innovative research, education, and clinical care. With over $300 million in research funding and a commitment to addressing pressing health challenges, MUSC fosters collaboration among faculty, staff, and community partners to translate scientific discoveries into impactful health solutions. The South Carolina Clinical & Translational Research Institute (SCTR) at MUSC supports innovative research across the translational spectrum, from basic science to population health, including patient-centered and community-engaged research.
The UCI Office of Research is dedicated to supporting and enhancing the creative and scholarly activities of UCI faculty and researchers. It provides central administrative support for research programs, ensuring compliance with regulations and fostering an environment conducive to research and innovation.
Cytonus Therapeutics is pioneering the convergence of artificial intelligence and synthetic biology to revolutionize drug development and delivery. The company challenges the high failure rates of traditional and precision medicines by developing next-generation therapeutics that are both highly effective and safe. Their mission is to create pragmatic shifts in how drugs are designed and administered, focusing on precision, safety, and efficacy to improve patient outcomes.
The Clemson University Research Foundation (CURF) is dedicated to advancing the research enterprise at Clemson University by connecting faculty and students with industry partners. CURF facilitates the commercialization of university technologies, supports research collaboration, and promotes innovation through various funding and support programs.
Hemerus Medical, LLC specializes in designing and developing innovative blood collection, processing, preservation, and storage technologies. Our mission is to improve patient transfusion outcomes and ensure the availability of high-quality, life-saving blood products. Hemerus aims to extend the shelf life of blood products and enhance transfusion safety through advanced technologies like leukocyte reduction filters and novel anticoagulant and additive solutions.
Virginia Tech is a leading research institution dedicated to improving the quality of life and the human condition through education, research, and community engagement. With a commitment to its motto, 'Ut Prosim' (That I May Serve), Virginia Tech fosters a collaborative environment that integrates technology into all disciplines, preparing scholars to be leaders and problem-solvers.
OsteoCure Therapeutics, a Duke University spinout and Johnson & Johnson JLABS company based in Durham, North Carolina, is developing OCTA1, a first-in-class injectable therapy designed to accelerate bone healing while simultaneously reducing pain. OCTA1 is a device led combination product that is composed of a hyaluronic acid scaffold with sustained-release microgels that deliver adenosine, a naturally occurring molecule critical for bone regeneration and pain modulation. Preclinical studies have demonstrated significant improvements in fracture healing and functional recovery, with strong statistical significance in both bone repair and analgesia. For civilian medicine, OCTA1 offers a minimally invasive, opioid-sparing solution for treating fusions, fractures, and other orthopedic trauma, enabling faster recovery for patients from athletes to older adults. In military medicine, the technology addresses critical needs in combat casualty care and training-related musculoskeletal injuries such as stress fractures, by providing a deployable, shelf-stable, and rapidly administered intervention that improves healing outcomes and reduces downtime, ultimately enhancing force readiness while also benefiting the long-term musculoskeletal health of veterans
LSU Health Sciences Center New Orleans is dedicated to educating future health professionals and scientists, advancing research, and providing exceptional healthcare. With six professional schools and numerous affiliated hospitals, LSUHSC-NO aims to improve health outcomes and address health equity challenges in Louisiana.
Lunai Bioworks Inc. is an AI-powered company at the intersection of drug discovery, diagnostics, and biodefense. The company integrates generative AI, proprietary neurotoxicity and chemical datasets, multi-omics, and high-throughput in vivo models to identify and validate therapeutic targets, biomarkers, and to safeguard against dual-use biosecurity risks. Lunai Bioworks partners with academia, industry, and government to advance safe and responsible AI-enabled biomedical innovation, spanning oncology, neurology, precision medicine, and countermeasure development for chemical and biological threats.
Relevium Medical is a pharmaceutical company based in Ireland and the US, founded in 2019 as a spin-out from the University of Galway’s BioInnovate Programme, the only European affiliate of Stanford BioDesign. With support from Y Combinator, Enterprise Ireland and the European Innovation Council, the company is developing novel hydrogel-based therapeutics for chronic disorders, leveraging natural biopolymers and active agents for targeted, long-lasting treatment. Relevium has a world-class clinical advisory board and a growing pipeline including products for osteoarthritis, painful bladder, neurogenic bladder, & trauma wound infections. To date the company has secured a total of $8 million non-dilutive funding and private seed investment.
Biophoundry specializes in advancing scalable engineered phage-based solutions for therapeutics, diagnostics, and bio-molecular engineering. It is shifting the paradigm from phage discovery to phage design. Its team leverages expertise in synthetic biology, machine learning, and data science to accelerate the development of precision antibiotics and address critical healthcare challenges such as antimicrobial resistance.
Northeastern University is a global research university founded in 1898, renowned for its experiential learning model, high-impact research, and deep partnerships. The university emphasizes innovative teaching and research that engage students, faculty, and alumni in solving real-world problems, fostering a dynamic and inclusive community across its 13 campuses worldwide.
The University of Montana (UM) is a flagship public research university located in Missoula, Montana. Established in 1893, UM offers a wide range of undergraduate and graduate programs, emphasizing research, creativity, and community engagement. With a commitment to academic excellence and public service, UM aims to transform lives through education and research, fostering a diverse and inclusive environment for its students.
CMTx Biotech, Inc. is an emerging biopharmaceutical company working to develop and commercialize host-directed therapeutics for the treatment of inflammatory and infectious diseases, as well as threat-agnostic medical countermeasures against high-priority chemical, biological, radiological and nuclear (CBRN) threats to homeland security and national defense. Our lead drug candidate is a clinically-tested, highly-stable, orally-administered small molecule that has been shown to improve survival and prevent lung injury in a wide variety of animal models of sepsis, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) across several species, including mice, rats, hamsters, pigs and sheep. Having already secured approximately $4M in funding to-date, including $3.6M in NIH SBIR/STTR grants, we are actively seeking non-dilutive funding, private investment capital and/or an established strategic partner to help advance human clinical trials and FDA Animal Rule development, as well as to expand our product pipeline.
The University at Buffalo is a leading public research university and flagship of the SUNY System, recognized for its innovative research and commitment to societal impact. It aims to transform scientific and technological breakthroughs into global impact, addressing complex challenges through interdisciplinary collaboration.
UC San Francisco is a leading university dedicated to advancing health worldwide through preeminent biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. With a commitment to public service, UCSF aims to innovate health care approaches for vulnerable populations and train the next generation of health professionals.
SUNY Upstate Medical University is a leading academic medical center in Central New York, dedicated to providing exceptional patient care, advancing medical research, and educating future healthcare professionals. As the region's only Level I trauma center and a Magnet recognized institution, Upstate is committed to delivering cutting-edge, life-saving treatments and fostering a compassionate, patient-centered environment. The university also plays a significant role in the community through outreach programs and is recognized as one of America's best large employers by Forbes.
Washington State University (WSU) is a public research university dedicated to improving lives by serving the public good. With a commitment to unlocking possibilities, WSU empowers students, faculty, and others to create a world where all people can thrive. The university offers a diverse range of academic programs across its six campuses and is recognized for its high research activity and community engagement.
Northstar owns IP around the use of antibody fragments and nucleic acids to rapidly diagnose and treat bacterial and viral infections. With numerous applications to sepsis and bioterrorism countermeasure, Northstar seeks partnerships with other forward thinking companies and government entities to protect our military and enhance homeland security.
UCLA is a leading public research university located in Los Angeles, California. It is renowned for its commitment to the creation, dissemination, preservation, and application of knowledge for the advancement of global society. With a rich history of academic and athletic excellence, UCLA offers a comprehensive environment that supports both academic and personal growth. The university is dedicated to fostering innovation and making a significant impact on the world through groundbreaking research and transformative practices.
Genomind is a leader in precision medicine for mental health, dedicated to helping healthcare providers and patients make better prescribing decisions by leveraging genetic, lifestyle, and environmental data. Their mission is to personalize mental health treatment and improve outcomes for individuals, providers, and healthcare systems. Genomind supports a wide range of stakeholders, including individuals, providers, long-term care facilities, ACOs, employers, health plans, and international partners. Through innovative pharmacogenetic testing, precision medicine software, consultative services, and educational resources, Genomind aims to advance mental health care and empower both patients and professionals.
The Office of Sponsored Programs (OSP) at Georgia Tech provides comprehensive support for research administration, including proposal preparation, contract negotiation, and compliance with federal and state regulations. OSP aims to facilitate research by offering educational resources, guidance, and administrative support to faculty and research administrators throughout the award lifecycle. Additionally, OSP is committed to improving and modernizing contract management processes, ensuring compliance with various agreements, and fostering collaborative research efforts.
Rx Bandz is dedicated to developing innovative, next-generation auto-injectors and life-saving formulations that provide simple solutions for patients, first responders, and the military. Their mission is to enhance the delivery of injectable medications, ensuring accessibility and ease of use for anyone, anytime, anywhere.
Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.
The Medical College of Wisconsin (MCW) is dedicated to transforming healthcare through innovative education, research, and patient care. With a focus on academic medicine, MCW aims to improve the health of communities by fostering a collaborative learning environment that integrates medical education with groundbreaking research and comprehensive patient care.
Ship of Theseus is a therapeutics company pioneering the development of degradation-resistant biologics based on the homeobox (HOX) family of transcription factors. By making proprietary modifications to HOX proteins, the company overcomes natural cellular mechanisms that rapidly degrade these powerful regulators, enabling their use as pharmaceuticals with longer-lasting effects. Their mission is to unlock the therapeutic potential of HOX proteins for a range of indications, including chronic wounds, stem cell expansion, and more, by creating innovative biologics that can safely and effectively modulate cell behavior.
Matisse Pharmaceuticals B.V. is a biopharmaceutical clinical stage company based in Geleen, The Netherlands. Founded in 2014, the company is dedicated to developing innovative therapies targeting life-threatening inflammation, particularly in sepsis and septic shock. Their mission is to save millions of lives by effectively neutralizing extracellular cytotoxic histones, with a vision to become the first company worldwide to effectively combat sepsis.
Indiana University is dedicated to building a better future through education, research, and community engagement. With a commitment to academic excellence, IU offers a diverse range of programs across its nine campuses, fostering an inclusive environment for over 90,000 students from around the world. IU is also at the forefront of groundbreaking research, particularly in areas such as brain health and Alzheimer's disease.
MyFitStrip is dedicated to enhancing oral and metabolic health through clinically-supported products that utilize the therapeutic potential of prebiotic formulations to boost nitric oxide levels. Delivered via topical oral lozenges and chewing gums, these products rapidly increase local nitric oxide concentrations to support a healthy oral microbiome and suppress pathogenic organisms in the oral and nasal cavities, which are key entry points and reservoirs for many infections, including COVID-19. By focusing on oral microbiome optimization, MyFitStrip promotes nitric oxide bioavailability, a molecule vital for vascular function, immune defense, and systemic wellness. The company's product line includes prebiotic chewing gums, slow-release lozenges, and personalized saliva test strips, all designed to support cardiovascular health, physical performance, respiratory resilience, and overall oral health.
ARIScience is at the forefront of drug discovery, leveraging a unique combination of AI, quantum chemistry, computer vision, and biochemistry to develop novel small molecule drugs. Their mission is to reduce the burden of human disease by discovering therapeutics that interrupt disease pathways. With a focus on neurodegenerative, inflammatory, and infectious diseases, ARIScience employs cutting-edge in silico methods to efficiently identify and optimize drug candidates. Their commitment to innovation and collaboration with leading institutions positions them to make a significant impact on human health. ARIScience is creating value in two ways: Value 1: ARIScience is developing small molecule assets targeting respiratory depression, cutaneous burn and radiation injuries, antivirals for EBOV and DENV, bacteriostatic antibiotic targeting Staph aureus. Value 2: It's novel AI driven quasi quantum chemistry (AI+QQ) small molecule discovery platform for precision protein inhibition and potentiation.
Akthelia Pharmaceuticals is a pioneering biopharmaceutical company focused on developing therapeutics that enhance the body's innate defense mechanisms to combat debilitating diseases. The company targets mucosal barrier injury and epithelial integrity through a novel immunotherapeutic strategy. Its mission is to revolutionize treatment for diseases such as cancer, infection, and autoimmune disorders by leveraging the body's own microbial defense mechanisms.
UConn Health is a vibrant, integrated academic medical center that is entering an era of unprecedented growth in academics, research, and clinical care. The campus hosts the Schools of Medicine and Dental Medicine with their respective graduate research programs, medical and dental clinics, and the UConn John Dempsey Hospital, rated as one of the World’s Best Hospitals for Infection Prevention and Patient Experience, and one of America’s Best-in-State Hospitals by Newsweek for the past four years. Recent investments in infrastructure, including new construction and renovated laboratory and teaching spaces, demonstrate a commitment to providing our faculty with access to the best possible infrastructure for scientific discovery, supporting Connecticut's and our region's need for innovation in service of our patients, transformative research, and society. We empower faculty, students, and industry partners to advance solutions that benefit Connecticut and the world, driving innovation, discovery, and societal impact through robust partnerships, state-of-the-art facilities, and a collaborative environment.
The University of Tennessee, Knoxville is dedicated to advancing knowledge and understanding through research, scholarship, and creative work. The Office of Research, Innovation, and Economic Development supports faculty, staff, and students in developing competitive proposals and fostering a strong culture of research integrity, aiming to create a more just, prosperous, and sustainable world.
OrthoTreat is dedicated to advancing bone regeneration through innovative solutions that enhance the body's physiological healing mechanisms. Their unique approach, OsteoRegulation, focuses on optimizing biological processes rather than merely providing materials for bone formation, aiming for faster, better, and stronger healing outcomes.
Founded in 2015, Omnix Medical is a clinical-stage biopharmaceutical company dedicated to developing novel antibiotic agents to combat infections caused by drug-resistant bacteria. Their innovative technology focuses on natural antimicrobial peptides, engineered for therapeutic use, targeting severe hospital-acquired infections and addressing the urgent threat posed by multidrug-resistant pathogens. The company is building a pipeline of first-in-class anti-infectives designed to treat severe, potentially lethal infections associated with multi-drug resistances.
Zymeron is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative healthcare technologies that deliver step-change performance. The company focuses on proactive health solutions to address critical unmet needs in the pharmaceutical sciences, particularly in drug delivery and formulation technologies.
Omniox is an IND-stage biotherapeutics company focused on developing innovative H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles. These biologics are designed to safely deliver oxygen to hypoxic tissues, addressing significant unmet medical needs and improving patient outcomes.
The Center for Military Medicine Research (CMMR) at the University of Pittsburgh is dedicated to advancing medical research for wounded service members and their families. The center focuses on trauma, emergency, and critical care, leveraging the university's strengths in medical and engineering fields, and collaborating with Carnegie Mellon University's robotics and AI expertise. CMMR aims to enhance trauma care for warfighters and civilians, contributing to the defense innovation economy.
The Texas A&M Engineering Experiment Station (TEES) is a state agency and part of the Texas A&M University System, dedicated to improving lives through engineering research, workforce development, and technology transition. TEES collaborates with industry, academia, and government to provide innovative solutions to global technical challenges.

Arizona State University
ASU Crosscutting Technologies to Enhance Military Medical Readiness and Resilience
Dr. Rachel Cassalia leads MTEC-supported efforts at ASU to shift military health from reactive care to proactive readiness through data-driven prevention.
University of Pittsburgh
Topical Metformin Lotion for Tendinopathy Prevention
University of Pittsburgh study shows topical metformin prevents overuse tendon injury. This work was sponsored through MTEC project 22-02-MPAI-014.
Theradaptive
Theradaptive’s RESTORE Trial Initiation for OsteoAdapt™ DE
Theradaptive launches RESTORE Phase I/II trial of OsteoAdapt™ DE for faster, precision bone healing in craniofacial injuries. MTEC-funded study targets improved recovery for military and civilian patients.
Altec
Autonomous Rehabilitation Device for Improved Recovery in Warfighters
The OSCIR platform—developed by Altec Inc in collaboration with the Naval Health Research Center—is bringing clinical-grade, real-time movement analysis to the front lines. Funded under MTEC-22-02-MPAI